Nematode GABA-A receptor
Complex group in Onchocercidae that 2 drugs act on.
- Drugs that act on it: 2
- Approved: 2
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| Diethylcarbamazine | Approved | Pfizer | Small molecule | Positive modulatorNematode GABA-A receptor positive modulator | 3 |
| Piperazine citrate anhydrous | Approved | — | Small molecule | Positive modulatorNematode GABA-A receptor positive modulator | 0 |
| Better Options for Lymphatic Filariasis Treatment | Diethylcarbamazine | Phase 3 | Recruiting | Medicines Development for Global Health | Sep 8, 2025 |
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis | Diethylcarbamazine | Phase 2 | Active, not recruiting | Washington University School of Medicine | Oct 6, 2023 |
| Host Response to Infection and Treatment in Filarial Diseases | Diethylcarbamazine | — | Active, not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Nov 4, 1999 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364676, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets